Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Biological criteria of eligibility for a treatment against EGFR].

Medecine sciences : M/S - 1 Mar 2009

Laurent-Puig Pierre

Abstract excerpt

The proteasome plays a pivotal role in the turnover of regulatory transduction proteins induced by activated cell membrane growth factor receptors. The epidermal growth factor receptor (EGFR) pathway is crucial in the development and progression of human epithelial cancers. The combined treatment with EGFR inhibitors has a synergistic growth inhibitory and pro-apoptotic activity in different human cancer cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Panitumumab

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Identifiers

PMID: 19361406
DOI: 10.1051/medsci/2009251s21

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Biological criteria of eligibility for a treatment against EGFR].PMID 19361406Read ↗

[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].Semantic proximity Read ↗

[EGFR/HER1: a target life].Semantic proximity Read ↗

Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Semantic proximity Read ↗

Rational bases for the development of EGFR inhibitors for cancer treatment.Semantic proximity Read ↗

EGFR signaling and autophagy dependence for growth, survival, and therapy resistanceSemantic proximity Read ↗

To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting InhibitorsSemantic proximity Read ↗

[PI3K and mTOR pathway and molecular targeted agents].Semantic proximity Read ↗

The epidermal growth factor receptor pathway: a model for targeted therapy.Semantic proximity Read ↗

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.Semantic proximity Read ↗

[Current development status and prospect of dual PI3K/mTOR inhibitors for cancer therapy].Semantic proximity Read ↗

[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].Semantic proximity Read ↗

Therapeutic targeting of the epidermal growth factor receptor in human cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.